Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution's experience.
Antoniou
C
C
Dessinioti
C
C
Stratigos
A
A
Avgerinou
G
G
Stavropoulos
P
P
Katsambas
A
A
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000139:chemically induced; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000139:chemically induced; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept